NxStage Expands System One (TM) Network Coverage for ESRD Patients

Friday, June 27, 2008
NxStage Expands System One (TM) Network Coverage for ESRD Patients

LAWRENCE, Mass., June 27, 2008 /PRNewswire-FirstCall via COMTEX/ ----NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that based on recent data compiled from its patient database matched with CMS public data, approximately 92 percent of End-Stage Renal Disease (ESRD) patients within the continental United States are now located within a 60 mile radius of a dialysis center which offers System One(TM) therapy.

"We are extremely pleased to have increased ESRD patient and physician access to System One via our comprehensive and growing network of dialysis centers," said Jeff Burbank, Chief Executive Officer. "We are committed to further develop and invigorate these programs to deepen our penetration and extend the quality of life benefits of home dialysis to more patients."

The Company also announced the appointment of Jeff Smith to the newly created position of Vice President and General Manager, Home Market. Mr. Smith joins NxStage from Insulet Corporation, where as Vice President of Marketing and Business Development he played a key role in commercializing a next generation wearable insulin pump for diabetes patients.

"Jeff is a strong addition to our team and rounds out NxStage's leadership capabilities across our three growing markets: home, critical care and in-center," said Burbank.

"Jeff will spearhead efforts intended to create momentum and grow our home market," said Joseph Turk, Senior Vice President, Commercial Operations. "He will be exclusively focused on building awareness and delivering tools that demonstrate the superior clinical and economic benefits associated with our home daily dialysis products to patients, physicians, providers and payors. Jeff brings exceptional marketing and commercial knowledge to this role, and has considerable experience in developing markets for medical devices," said Turk.

Mr. Smith joins two other seasoned executives, John Westman and Mark Florence, who serve as Vice Presidents and General Managers of NxStage's Critical Care and In-Center/Medisystems Markets, respectively. Mr. Florence joined NxStage in January 2008, and Mr. Westman has been leading the critical care team since September 2005.

Mr. Smith served four years with Insulet Corporation after serving for 22 years with Abbott Labs in various roles, most recently as Divisional Vice President of Medisense, Abbott's consumer diabetes care franchise. Prior, Mr. Smith was General Manager of Abbott Diagnostics (Canada) and was Director of Ross Products Sales and Marketing.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan" and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Messrs. Smith, Florence and Westman will make to the Company's performance and operating results, expectations as to the growth in our three markets, and expectations as to the development of the home dialysis market, in particular. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the period ending March 31, 2008. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact: Kristen K. Sheppard, Esq. VP, Investor
Relations 978-332-5923 ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.